Remepy Closes $15M Seed Funding
Summary
Remepy, a New York-based hybrid drugs developer, closed a $10M seed funding round, which, together with earlier funding, totalled $15M. Led by Dr. Michal Tsur, and Or Shoval, Remepy is pioneering Hybrid Drugs, which are traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments. Digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs. The company has already proven in human studies the effect of its products, using extensive brain imaging, as well as blood and saliva samples, with promising results for Oncology, MCI, and Parkinson’s Disease.